Last reviewed · How we verify
corticosteroids (Aprednislon)
corticosteroids (Aprednislon) is a Corticosteroid (glucocorticoid) Small molecule drug developed by Ingrid Pabinger, MD. It is currently FDA-approved for Inflammatory and autoimmune conditions (specific approved indications not clearly documented in available sources). Also known as: Aprednislon.
Aprednislon is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Aprednislon, a small molecule corticosteroid, is used to treat various conditions including Rheumatoid Arthritis, Alcoholic Hepatitis, Alcoholic Liver Disease, and Systemic Sclerosis, as indicated by ClinicalTrials.gov. The exact mechanism of action of Aprednislon is currently unknown, according to ChEMBL.
At a glance
| Generic name | corticosteroids (Aprednislon) |
|---|---|
| Also known as | Aprednislon |
| Sponsor | Ingrid Pabinger, MD |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / General anti-inflammatory |
| Phase | FDA-approved |
Mechanism of action
As a corticosteroid, Aprednislon acts as a glucocorticoid receptor agonist, translocating to the nucleus to modulate gene expression and reduce production of inflammatory mediators including TNF-α, IL-1, and IL-6. This broad immunosuppressive effect reduces inflammation, swelling, and immune-mediated tissue damage across multiple organ systems.
Approved indications
- Inflammatory and autoimmune conditions (specific approved indications not clearly documented in available sources)
Common side effects
- Immunosuppression / increased infection risk
- Hyperglycemia
- Osteoporosis (with chronic use)
- Hypertension
- Adrenal suppression
- Mood changes / psychiatric effects
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- OMT for Adhesive Capsulitis (PHASE4)
- Corticosteroid Tapering in Sarcoidosis (NA)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (PHASE1, PHASE2)
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- corticosteroids (Aprednislon) CI brief — competitive landscape report
- corticosteroids (Aprednislon) updates RSS · CI watch RSS
- Ingrid Pabinger, MD portfolio CI
Frequently asked questions about corticosteroids (Aprednislon)
What is corticosteroids (Aprednislon)?
How does corticosteroids (Aprednislon) work?
What is corticosteroids (Aprednislon) used for?
Who makes corticosteroids (Aprednislon)?
Is corticosteroids (Aprednislon) also known as anything else?
What drug class is corticosteroids (Aprednislon) in?
What development phase is corticosteroids (Aprednislon) in?
What are the side effects of corticosteroids (Aprednislon)?
What does corticosteroids (Aprednislon) target?
Related
- Drug class: All Corticosteroid (glucocorticoid) drugs
- Target: All drugs targeting Glucocorticoid receptor (GR)
- Manufacturer: Ingrid Pabinger, MD — full pipeline
- Therapeutic area: All drugs in Immunology / Rheumatology / General anti-inflammatory
- Indication: Drugs for Inflammatory and autoimmune conditions (specific approved indications not clearly documented in available sources)
- Also known as: Aprednislon
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing